Emblem Corp. (TSX-V:EMC) (TSX-V:EMC.WT) and Canntab Therapeutics Limited (CSE:PILL) announced this morning that they have received approval from Health Canada for research and development of cannabinoid based products with an oral sustained release formulation.
Development and processing equipment has arrived tp Emblem’s Paris, Ontario location and the companies will begin making the first pivotal batch of products this week using its patented technology and proprietary processes. The initial batch will be rigorously testing by third-party laboratories. After the R&D Emblem and Canntab intend to submit their products to
Health Canada for review and approval.
Emblem and Cannta will be collaborating on the formulation, clinical development, regulatory approval and commercialization of a range of additional cannabinoid containing pharmaceutical formulations.
“The extended release tablet is the perfect pharmaceutical dosage form. It’s a game changer for the medical community and solves many problems for patients. We are excited to be working with Emblem to bring this innovative product to market,” said Jeffrey Renwick, CEO of Canntab, in the press release.
You may be interested
Columbia Care Receives Licenses from Maltese GovernmentEditor - November 15, 2018
Columbia Care LLC. has announced this morning that the company has gain approval from Malta Enterprises, the regulatory economic development agency in the country, to receive licenses…
Tilray Announces Impressive 2018 Q3 FinancialsEditor - November 14, 2018
Wholly-owned subsidiary of Privateer Holdings, Inc., Tilray (NASDAQ: TLRY), has announced the company’s third quarter financial statements for 2018 this morning. Earlier this year, Tilray debuted its…
Valens Signs Cannabidnoid Extraction and R&D Agreement with Harvest OneEditor - November 14, 2018
Valen GroWorks Corp. (CSE: VGW) (OTC-QB: MYMSF) has announced this morning that the company has entered into an agreement with Harvest One (TSXV:HVT) to provide services in…